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Abstract
Introduction. Blood- borne infections are a major cause of harm in individuals on haemodialysis (HD). In particular, knowledge 
about hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) status in HD patients is a major concern, 
since these infections may cause comorbidities in this setting. There is a paucity of data regarding this issue in Argentina.
Hypothesis/Gap Statement. The epidemiological surveillance of HBV, HCV, and HIV is a fundamental tool for planning and 
implementing health strategies in order to prevent and control viral transmission of these viral agents.
Aim. To determine the seroprevalence of HBV, HCV and HIV infections in HD patients in Buenos Aires, Argentina.
Methodology. Seven hundred and forty- eight HD patients were included in a retrospective cross- sectional study. Serologi-
cal assays were performed to determine HBV, HCV and HIV status. HBV HBsAg and anti- HBc IgG were analysed using AxSYM 
(samples before 2010) or the Architect Abbott system (samples since 2010), anti- HCV IgG testing was performed using the 
anti- HCV enzyme immunoassay AxSYM HCV V3.0 and ARCHITECT anti- HCV, while HIV was tested for using AxSYM HIV 1/2 gO 
and ARCHITECT HIV Ag/Ab Combination. HCV genotyping was carried out by phylogenetic analysis of the NS5B partial gene.
Results. Infection with one of the viruses was detected in 31.1 % of patients [HBV in 82 (11.0 %), HCV in 179 (23.9 %) and HIV in 
6 (0.8 %)]. Thirty- two (4.3 %) patients had 2 virus markers [27 (3.6 %) with HCV/HBV, 4 (0.5 %) with HCV/HIV and 1 (0.13 %) with 
HBV/HIV]. Finally, a single patient (0.13 %) presented all three markers. Time on dialysis was correlated with HCV but not with 
HBV infection. The HCV subtype distribution in HD patients was inverted with respect to that observed in the general population 
(HCV- 1a 73.2 % and HCV- 1b 26.8 % in HD vs HCV- 1a 26.5 % and HCV- 1b 73.5 % in the general population, P <0.001).
Conclusion. Despite the implementation of universal precautionary biosafety standards for dialysis, infection with HBV and HCV 
continues to occur at very high rates in HD patients. The results emphasize the need to carry out proactive tasks for early diag-
nosis and treatment of infected individuals and to vaccinate those with non- protective antiHBs antibodies in order to reduce 
morbidity and mortality in HD patients.
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INTRODUCTION
The prevalence rate for dialyzed patients in Argentina is 
637 patients per million individuals (approximately 29 700 
patients), with haemodialysis (HD) being the most widely 
applied treatment for patients with end- stage renal disease 
[1]. Blood- borne viruses, such as hepatitis B (HBV), hepa-
titis C (HCV) and human immunodeficiency virus (HIV), 
have a consistently higher prevalence among HD patients 
than in the general population [2]. This finding may be due 
to several factors, including repeated and prolonged access 
to the bloodstream, the simultaneous treatment of multiple 
patients in the same facility, and the lack of effective biosafety 
measures [2]. This issue is a major healthcare concern, since 
these viruses are a significant cause of increased morbidity 
and mortality [3]. The prevalence rate varies among countries 
and even among health centres within the same area [2, 4–6]. 
Coinfection is a common finding among HD patients and it 
may be associated with the worst clinical outcomes [7–9].
No large- scale dialyzed patient prevalence studies for HBV, 
HCV and HIV have been conducted in Argentina. Flichman 
et al. reported a low infection prevalence in blood donors 
tested nationwide [10]. The authors analysed the prevalence 
of HBsAg (0.19 %), anti- HCV (0.46 %) and anti- HIV (0.20 %) 
titres in more than two million samples.
With regard to the Argentine population undergoing dial-
ysis, data are unfortunately fragmented and dissimilar. The 
Argentine Chronic Dialysis Registry reports a prevalence of 
1.02, 2.40, and 0.91 % for HBsAg, anti- HCV and anti- HIV, 
respectively [1]. Other studies conducted on different dialysis 
populations from Argentina showed a significantly higher 
prevalence for HCV, ranging from 10.6–38.0 % [11–14]. 
Disparities in reported HCV prevalence rates as well as a 
paucity of data for HBV and HIV warrant the present research 
work. Therefore, the main goal of this study was to estimate 
the prevalence of HBV, HCV and HIV among HD patients 
from the Ciudad Autónoma de Buenos Aires, Argentina.
METHODS
Study population
In this retrospective cross- sectional study, patients on HD 
were tested for anti- HCV, HBsAg and anti- HIV as part of 
a screening programme conducted at Centro de Educación 
Médica e Investigaciones Clínicas Norberto Quirno 
(CEMIC), a university hospital located in Buenos Aires, 
Argentina. Samples were collected between January 2001 
and December 2018.
Laboratory assays
HBV HBsAg and anti- HBc IgG were analysed using AxSYM 
(Abbott Diagnostics, USA; samples before 2010) and the 
Architect Abbott system (Abbott Diagnostics, Wiesbaden, 
Germany; samples since 2010). Anti- HCV IgG testing 
was performed using the anti- HCV enzyme immunoassay 
AxSYM HCV V3.0 (Abbott, Wiesbaden, Germany) and 
ARCHITECT anti- HCV (Abbott Wiesbaden, Germany). 
HIV was tested for using AxSYM HIV 1/2 gO (Abbott, 
Wiesbaden, Germany) and ARCHITECT HIV Ag/Ab 
Combination (Abbott Wiesbaden, Germany). All tests were 
performed following the manufacturers’ recommendations.
HCV genotyping, RT-PCR and sequencing
Serum RNAs were extracted with Magna Pure (Roche) 
following the manufacturer’s instructions. Reverse tran-
scription was carried out with MMLV- RT (Promega) 
with random hexamer primers using the manufacturer’s 
protocol. The amplification of the HCV NS5B partial region 
was performed as described previously [15]. Subsequently, 
the amplified DNAs were purified and then sequenced in 
both senses (Instituto Nacional de Tecnología Agropec-
uaria, Castelar, Argentina).
Phylogenetic analysis and HCV genotype
A broad sequence search was performed using keywords 
on the National Center for Biotechnology Information 
(NCBI) central nucleotide search website (https:// blast. 
ncbi. nlm. nih. gov/ Blast. cgi? PROGRAM= blastn& PAGE_ 
TYPE= BlastSearch& LINK_ LOC= blasthome) to retrieve 
sequences of HCV containing NS5B regions. One hundred 
and fifty- nine sequences were randomly selected so that 
all HCV genotypes and each of the geographical regions 
of interest were represented. NS5B sequences were aligned 
with clustalx v2.0 software. A maximum- likelihood (ML) 
phylogenetic tree was estimated using IQ- TREE v1.6.12 
software, setting the model parameters according to those 
suggested by the Bayesian information criterion [16]. 
A non‐parametric ultrafast bootstrap analysis of 10 000 
replicates was carried out for branch support. In order to 
verify the obtained results, a Bayesian phylogenetic analysis 
was simultaneously carried out with MrBayes v3.2.7a [17]. 
Analyses were run for five million generations, and sampled 
every 5000 generations. Convergence of parameters [effec-
tive sample size (ESS) ≥200, with a 10 % burn- in] was veri-
fied with Tracer v1.7.1. Phylogenetic trees were visualized 
with FigTree v1.4.4.
Statistical analysis
Continuous variables were expressed as a median (Q1–Q3) 
and categorical variables as a number (percentage). Student’s 
t- test and the Mann–Whitney U test were used for comparing 
continuous variables. The statistical analysis was carried out 
using the SPSS statistical software package release 19.0 (IBM 
SPSS, Inc., Chicago, IL, USA).
RESULTS
Characteristics of the study population
A cohort of 748 patients was analysed; the median (Q1–Q3) 
age was 59 (44–70) years old and 410 (54.8 %) were male. 
Sixty- three out of 748 (8.4 %) were kidney transplant patients 
and 182 (24.3 %) had received blood transfusion. Median 
(Q1–Q3) time on dialysis treatment was 25 (7–76) months.
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Prevalence of HBV, HCV and HIV infection
Infection with one of the three viruses was detected in 233 
(31.1 %) subjects from the cohort. Thus, 515 (68.9) patients 
were not infected by any of the studied viruses. The median 
age (Q1–Q3) of the uninfected patients was 61 (48–73) and 
292 (56.7) were male. Table 1 summarizes the characteristics 
of the study population according to infection by any of the 
three considered viruses. Thirty- two (4.27 %) patients had 
markers of infection with two virus types [27 (3.6 %) with 
HCV/HBV, 4 (0.5 %) with HCV/HIV and 1 (0.13 %) with 
HBV/HIV]. Finally, only one patient (0.13 %) presented all 
three virus type markers.
HBsAg and anti- HBc IgG were detected in 82 patients 
(11.0 %), 43 female and 39 male. Thus there was a similar 
distribution of positive cases between genders (12.7 % female 
vs 9.5 % male, P=0.162). Neither patient age nor time on 
dialysis were statistically associated with HBV infection. 
In this sense, patients infected with HBV were 60 (44–69) 
years old and the uninfected ones were 58 (44–71) years 
old, P=0.984. When considering time on dialysis, patients 
infected with HBV had been on dialysis for 19 (4–156) 
months, while those uninfected had attended dialysis for 26 
(8–74) months, P=0.927. No association was found between 
transfusion history and the risk of acquiring HBV [2 trans-
fused individuals (4.2 %) and 10 non- transfused ones (6.7 %), 
P=0.521]. There was no association between HBV detection 
and plasma levels of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST). Thus, subjects infected 
with HBV showed ALT 15 IU l−1 (11–26) and AST 17 IU l−1 
(11–23), whereas the corresponding figures among non- HBV 
infected patients were 15 IU l−1 (11–24) for ALT, and 15 IU 
l−1 (11–21) for AST (P=0.911 and P=0.572 for ALT and AST, 
respectively).
Regarding HCV, anti- HCV was detected in 179 (23.9 %) 
patients. Plasma HCV RNA, indicative of active HCV 
infection, was detected in 125 (69.8 %) patients. There was 
no significant gender- related variation for positive cases [80 
females (23.7 %) and 99 males (24.1 %), P=0.879]. Unlike the 
findings for HBV, HCV infection in dialyzed patients was 
statistically associated with age [62 (48–72) years old for the 
uninfected subjects and 49 (39–61) years old for the infected 
ones, P <0.001], and with the time on dialysis [19 (6–46) 
months for uninfected patients and 101 (31–154) months for 
the infected ones, P <0.001]. In addition, subjects without 
transfusion history showed the highest number of HCV cases 
[40 non- transfused individuals (26.8 %) versus 5 transfused 
(10.4 %), P=0.018]. Finally, ALT and AST were higher in 
patients infected with HCV. Thus, patients with HCV showed 
ALT 24 IU−1 (15–41) and AST 21 IU l−1 (14–32), whereas the 
levels for non- HCV infected patients were 14 IU l−1 (11–20) 
for ALT and 14 IUl−1 (11–19) for AST (P <0.001 for both ALT 
and AST).
HIV showed the lowest prevalence. Only 6 (0.8 %) patients 
were positive for anti- HIV. Statistical analysis for age, years 
of attending dialysis, gender, or transfusion history was not 
possible due to the small number of positive cases.
HCV genotype distribution and phylogenetic 
analysis
As result of the particularly high prevalence of HCV infection 
found in this work, a phylogenetic analysis of HCV sequences 
was carried out in order to determine and compare the geno-
type of HCV infecting dialyzed patients to those infecting 
individuals from the general population.
Nucleotide sequences from the NS5B region of 43 out of 
179 HCV- positive cases were analysed. The genotype distri-
bution obtained by phylogenetic analysis was 30 (73.2 %) 
HCV- 1a, 11 (26.8) HCV- 1b, 1 (2.3 %) HCV- 2c and 1 (2.3 %) 
HCV- 3a.
Table 1. Characteristics of the study population by infection
Parameter Total, n (%) Uninfected, n (%) Infected patients, n (%)* P
Patients 748 (100) 515 (68.85) 233 (31.15) –
Age 59 (44–70) 61 (48–73) 53 (40–65) <0.001
Gender
  Male (%)
  
410 (54.8) 292 (56.7) 118 (52.9) 0.123
  Female (%) 338 (45.2) 223 (43.3) 115 (47.1)
Months on dialysis (Q1–Q3)† 25 (8–77) 20 (6–47) 98 (26–149) <0.001
Transfusion‡ 48 (24.4) 42 (28.9) 6 (11.5) 0.012
ALT, IU/L (Q1–Q3) 15 (11–24) 14 (11–20) 20 (13–37) <0.001
AST, IU/L (Q1–Q3) 15 (11–21) 14 (11–19) 19 (13–28) <0.001
*Infected patients, patients infected by HBV, HCV or HIV.
†Available for 184 patients.
‡Available for 197 patients.
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NS5B sequences from dialyzed patients infected with HCV-1 
were compared to those from 68 HCV-1- infected patients 
who attended the same hospital but did not undergo HD 
during the same period. In this cohort, the distribution of 
subtypes was significantly different: 50 (73.5 %) HCV- 1b and 
18 (26.5 %) HCV- 1a, P <0.001.
Patient age was statistically associated with HCV-1 subtypes 
distribution [51 (47–58) years old for HCV- 1a and 59 (50–66) 
years old for those infected with HCV- 1b, P=0.008]. On the 
other hand, there was no significant differences in subjects’ 
ages for HD patients and subjects attending the same hospital 
[51 (45–64) years old and 57 (49–62) years old, respectively, 
P=0.293].
Phylogenetic analysis showed the formation of one supported 
cluster belonging to HCV- 1a. This cluster comprising 
sequences D005, D014, D015 and D016 from patients 
undergoing dialysis was the only one confirmed by both 
phylogenetic approaches, ultrafast bootstrap and Bayesian 
analysis (Fig. 1).
DISCUSSION
The determination of the prevalence of blood- borne infec-
tions in the haemodialysis (HD) setting is useful to estab-
lish the status of the population undergoing dialysis and to 
monitor the effectiveness of the implemented sanitary and 
strategies and to identify their achievements and limitations. 
To our knowledge, this is the first large- scale survey that 
analyses HBV, HCV and HIV viral markers in a population 
undergoing HD in Argentina.
It is well known that the dialysis procedure plays a prepon-
derant role in the transmission of HBV and that prevalence 
mostly depends on the baseline population rates [2, 18]. In 
developed countries, HBV prevalence in dialysis centres 
varies between 0 and 6.6 %, while in developing countries 
it ranges more widely between 1.3 and 14.6 % [18]. In the 
present study, the prevalence of HBsAg was consistent with 
that found in low- income countries. This high prevalence 
could be a consequence of the low coverage rate of HBV 
vaccination (less than 40 %) in populations not reached by 
mandatory vaccine schedules [1, 19]. Other reason may be 
an upward trend of new HBV cases, observed in the last 
10 years, in people 20 to 59 years old who represent a large 
proportion (49 %) of HBV- infected individuals in the present 
study [20]. In this scenario, it is crucial to increase the HBV 
vaccination coverage and to improve the standard precautions 
and/or dialysis- specific procedures in order to prevent disease 
dissemination in our country.
Interestingly, no association was found between HBV infec-
tion and time on dialysis. A possible explanation may be the 
fact that, as is known in our country, most patients who start 
dialysis are not vaccinated against HBV. However, once they 
start treatment, they are immediately vaccinated. In this way, 
it has been observed that protection levels against HBV are 
approximately 30 % in the first 5 months of dialysis and that 
they reach up to 80 % at 15 years under treatment [1].
Fig. 1. HCV ML phylogenetic tree (TIM2+F+I+G4 model for nucleotide 
substitutions) for the NS5B partial region (314nt). Branch lengths 
are proportional to the evolutionary distance between the samples. 
Numbers on each node represent the ultrafast bootstrap support 
(branch support >70 % is shown). Samples are identified as follows: 
sequences obtained in this work have symbols before their names 
representing the source – solid circle, dialysis; empty circle, no dialysis 
– while sequences without symbols are those chosen randomly from 
GenBank.
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With regard to HCV, almost a quarter of analysed patients were 
positive. This prevalence is within the previously reported 
range in our country for patients undergoing dialysis and it is 
significantly higher than that described in the general popula-
tion [13, 14, 21, 22]. This situation is repeated all over the 
world, with people who attend HD centres being a high- risk 
group for HCV infection [2, 6]. In addition, prevalence was 
associated with time on dialysis. In this sense, the majority of 
HCV- infected patients were younger but had a longer treat-
ment history. These data coincide with previously published 
data also reporting that dialyzed patients do not have the same 
age- based epidemiological distribution for HCV infections. A 
similar situation has previously been described in Argentina 
[1, 14] and other parts of the world [2].
HCV genotype distribution in HD patients is a valuable tool 
to understand the transmission routes. Some studies have 
found a matching distribution of genotypes among patients 
undergoing dialysis and the general population, while others 
observed a frequency bias [23]. In Argentina, HCV- 1b has 
been reported as the most prevalent subtype, both in the 
general population and in dialyzed patients [12, 24]. This 
subtype has been associated with older individuals and 
patients who received transfusions [25]. Unexpectedly, in 
the cohort included in this study, a high prevalence of HCV- 
1a, which has mostly been found in younger individuals and 
intravenous drug users, was observed [25, 26]. However, in 
the present study, even when HD patients were younger, no 
significant differences were found between both populations 
(HD and ambulatory patients). Therefore, this finding could 
be a consequence of an epidemiological change in HCV in 
Argentina, where it has been stated that although HCV- 1b 
entered earlier in the country it is currently on a demographic 
plateau, while HCV- 1a was introduced later but is still in a 
growing phase [27]. Moreover, the greater prevalence of 
the HCV- 1a genotype determined in the present study was 
similar to that described in other risk groups such as HCV/
HIV individuals, trans- sex workers and intravenous drug 
users [21, 28–30]. Additionally, a lower prevalence of HCV-2 
and HCV-3 has been detected in dialyzed patients, compared 
to that previously reported in the general population [14, 31].
As stated for HBV, the prevalence of HIV in patients under-
going dialysis largely depends on the local prevalence in the 
general population [4]. In this study, the observed prevalence 
has been higher than that described in the general population 
but close to that reported by the Argentine Chronic Dialysis 
Registry [1, 32].
Unfortunately, there are no large- scale studies of nosocomial 
infections in dialyzed patients from Argentina. The only 
information about outbreaks of HCV or HBV in dialysis 
facilities in Argentina is restricted to congress publications. 
In this context, Besonne et al., reported an outbreak of HBV 
and HCV in HD patients in the city of Rosario, Argentina 
[33, 34]. However, several studies worldwide have indicated 
that the prevalence of HBV, HCV and HIV tends to be higher 
in patients in dialyzing settings than in the general popula-
tion [2, 6]. This finding suggests a close association between 
undergoing dialysis and being infected. The availability of 
better facilities and more trained staff has been associated 
with significantly decreased HCV and HBV prevalence [2], 
so prevention measures seem not to be sufficiently effective. 
On the other hand, in Argentina, nosocomial outbreaks of 
HIV have not been reported since 1993 [11]. As a result, the 
positive cases found in this study may be a consequence of 
the progression to end- stage renal disease (ERSD) due to HIV 
infection rather than a consequence of the dialysis procedure 
itself. It is well known that the risk of progression to ERSD 
is significantly higher in HIV- seropositive patients [4, 35]. 
Progression to ERSD has increased in recent years due to the 
greater longevity of HIV- infected patients, thanks to antiret-
roviral therapy efficacy [36].
The present work has some limitations. One of these is the 
lack of information about of HBV, HCV and HIV patient 
status prior to dialysis. However, when considering data 
from the general population, we can attribute the identified 
high prevalence to the risk associated with HD. Second, the 
serological tests were not confirmed by nucleic acid detec-
tion. Third, the time undergoing treatment is unknown for 
some patients. However, we had sufficient data to perform the 
statistical analysis. Lastly, the samples included in this study 
came from a single centre in Buenos Aires and prevalence can 
vary significantly between dialysis units [2, 4–6]. Therefore, 
despite the size of the cohort, caution should be exercised in 
extrapolating the results to the whole country. Nevertheless, 
more than one- third of the Argentinean population lives in 
the area of Buenos Aires, so the study can be regarded as an 
acceptable approximation of the current situation.
Overall, almost one- third of the studied patients presented 
one of the three analysed viruses. Unfortunately, the imple-
mentation of universal precautionary biosafety standards 
in dialysis units would appear to be insufficient to contain 
blood- borne infections. Further efforts, such as HBV vaccina-
tion and HCV treatment with new drugs, highly trained staff 
and better facilities will be required to prevent HD patients 
from continuing to be a vulnerable population at high risk of 
acquiring blood- borne infections. In addition, HCV subtype 
distribution was uneven compared to the general population. 
Finally, these study findings could contribute to the planning 
and implementation of health strategies in order to reduce 
the transmission of infections in the dialysis setting, as well 
as monitoring and evaluation of their effectiveness.
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